⚑ The last run on this idea flagged:
idea-023 · human · US
For prescription use by or under the direction of a healthcare professional in; hospital, outpatient wound clinic, skilled nursing facility and home health settings, to; cleanse, irrigate and mechanically remove debris, exudate and foreign material from acute; and chronic dermal wounds in adults (Stage 2-4 pressure injuries, venous and arterial leg; ulcers, diabetic foot ulcers, post-surgical and traumatic wounds, and first- and; second-degree burns), at each dressing change. A sterile, hypochlorous acid-preserved saline; irrigation solution, supplied in a bag for multiple use within a single patient over its; labelled in-use period, is delivered at each irrigation session through a single-use,; three-nozzle spray head with an integral splash shield that is connected to the bag at the; point of use, at an irrigation pressure within 4-15 psi. The hypochlorous acid acts as a; preservative of the solution. No claim is made that it kills microorganisms in the wound or; treats or prevents wound infection.
Finished enough to read, and waiting for you. 7 of 7 departments answered: 6 conditional, 1 abstaining, none blocking. 94 of 212 claims verified, 2 refuted. 0 of 8 things it rests on are critical and open; the first is cheap to find out.
⚑ The shape changed during this run (pivot P0 the original shape → P1 per-patient HOCl bag, recorded as a redesign on 2026-10-04): what is described here is not the kit as first referred. A system for cleaning acute and chronic wounds at each dressing change, in US hospitals, outpatient wound clinics, nursing homes and home care. It has two parts. A sterile bag of saline preserved with hypochlorous acid is opened once and kept for one patient over a labelled number of days. A fresh, single-use spray head with three nozzles and a splash shield is plugged into that bag at every session, and the nurse squeezes a chamber in the head to push the fluid out at the pressure wound guidelines recommend (4-15 psi). It started as the referrer's "Aquaceso" irrigator (bag, three-nozzle head, splash shield, warmed tap water or irrigation fluid), with hypochlorous acid in place of water. It changed shape because FDA (US Food and Drug Administration)'s 2023 proposed rule for wound washes accepts hypochlorous acid as a preservative only in a wash that is nonsterile or reused for one patient, not in a sterile single-use product, and because a bag squeezed by hand reaches only about 4 psi. Warming was dropped. On the label the hypochlorous acid only keeps the opened bag from growing organisms; it makes no claim to kill germs in the wound or help healing, since that would make it a drug, and no adequately sized trial showing it beats saline has been found. No US payer pays for it separately (Medicare lists wound cleansers as non-covered, and facility payments are bundled), so a facility would buy it out of its own supply budget. It is coded to existing FDA wound-wash and irrigation routes, and in Europe it would be a medical device under the MDR (medical device report), which has not been checked here.
A wound nurse cleans a chronic wound at each dressing change. She may work in a US hospital, an outpatient wound clinic, a skilled nursing facility, or on a home health visit. Today she uses saline and a syringe, or pours from a bottle or bag of an HOCl cleanser that is already cleared claim 6verified. The bet is that her employer will buy a system instead. It has two parts:
In the Wrap's one-paragraph version, written for someone who has not opened the file. Domain: acute-chronic-wound-cleansing-irrigation
The chain is the same in every US setting. A facility or agency writes the cheque out of a supply budget, and that budget is funded by a bundled payment that does not move when it buys this product. One exception sits outside the chain: a bag sent home with the patient, where the patient pays.
apc has no Addendum B cache. That is a tooling gap, and it does not change who buys.
unconfirmed. No connector reaches a Danish source. Nothing in the US chain above stands in for Denmark.
What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.
What would settle it (cheap): twenty structured calls with US value-analysis committees and supply-chain buyers on the instrument Commercial designed under REQ-0225 Design, which carries claims 161 and 162 (fieldwork the owner must authorise), with the Vashe Federal Supply Schedule contract price for claim 131unconfirmed retrieved first; the per-session cost test (claim 188unconfirmed) follows once REQ-0244 For P1 gives a price and volumes and a bill of materials exists
claim 161unconfirmed, claim 188unconfirmed, claim 117unconfirmed, claim 37unconfirmed, claim 36unconfirmed, claim 131unconfirmed, claim 165unconfirmed, claim 166unconfirmed, claim 34verified, claim 68verified, claim 69verified, claim 105verified, claim 103verified, claim 104verified, claim 29verified, claim 65verified, claim 66verified, claim 67verified, claim 164verified
What would settle it (cheap): Regulatory's answer to REQ-0255 P1's mechanism makes the single-use head… (whether FDA accepts a non-standard, maker-keyed port on a wound-irrigation bag) and Technology's answer to REQ-0234 In the P1 reference design (whether keying and resealing can share one connector), both answerable from records and engineering judgement; the buyer half is carried by the same calls that settle B1 US hospitals
What would settle it (cheap): a human download of the Nordjylland tender documents and award notice from TED or EU-Supply (REQ-0201 For Region Nordjylland's joint wound tender, REQ-0236 For Region Nordjylland's joint wound tender), because the TED host blocks automated fetch; then a notified-body certificate search and a European patent search, which no connector here reaches
claim 21unconfirmed, claim 22unconfirmed, claim 112unconfirmed, claim 135unconfirmed, claim 26unconfirmed, claim 113unconfirmed, claim 115unconfirmed, claim 132unconfirmed, claim 133unconfirmed, claim 134unconfirmed, claim 170unconfirmed, claim 171unconfirmed, claim 159unconfirmed
What would settle it (project): REQ-0228 Retrieve the labelled storage condition first, the Puracyn Plus labelled in-use period and port design (one retrieval, named by three chairs as their cheapest move); then a short in-use run on prototype bags from a candidate filler, which needs a filler request for information that the owner must authorise
claim 167unconfirmed, claim 177unconfirmed, claim 168unconfirmed, claim 174unconfirmed, claim 189unconfirmed, claim 163unconfirmed, claim 126unconfirmed, claim 127unconfirmed, claim 71unconfirmed, claim 128unconfirmed, claim 190unconfirmed, claim 119verified, claim 122verified, claim 176verified, claim 169verified, claim 178verified, claim 125verified, claim 6verified, claim 110verified
What would settle it (project): a bench rig on a prototype head of defined geometry (REQ-0249 For the P1 head assembly, REQ-0239 For the P1 reference head) measuring delivered pressure across operators, cycle life, and chlorine and droplets in the breathing zone; the in-hand clinical comparison (claim 172unconfirmed) comes after and needs funding
claim 145unconfirmed, claim 172unconfirmed, claim 192unconfirmed, claim 147unconfirmed, claim 191unconfirmed, claim 148unconfirmed, claim 51unconfirmed, claim 143verified, claim 86verified, claim 70verified, claim 16verified, claim 88verified, claim 89verified, claim 99verified, claim 100verified
What would settle it (project): first the referrer's answer on who makes and owns Aquaceso (REQ-0224 Ask the referrer and REQ-0208 Obtain from the referrer, one message the owner sends); then the head geometry from REQ-0249 For the P1 head assembly, the landscape searches REQ-0212 Run a recorded and REQ-0248 Run a recorded US landscape, and counsel's read of the named families against that geometry, which the owner must engage
claim 3unconfirmed, claim 155unconfirmed, claim 193unconfirmed, claim 194unconfirmed, claim 52verified, claim 85verified, claim 149verified, claim 150verified, claim 83verified, claim 157verified, claim 56verified, claim 151verified, claim 152verified, claim 181verified, claim 182verified, claim 183verified, claim 184verified, claim 185verified, claim 186verified, claim 187verified, claim 154verified, claim 156verified, claim 81verified
What would settle it (project): REQ-0254 Search openFDA 510, a records search for any separately sold, hand-operated, container-fed head cleared under FQH or KYZ; only FDA settles the head, through a 513(g) request or a Pre-Submission, and either one discloses the opportunity outside the organisation, which makes it the owner's decision
claim 180unconfirmed, claim 179verified, claim 12verified, claim 120verified, claim 121verified, claim 4verified, claim 13verified, claim 14verified, claim 17verified, claim 124verified, claim 144verified
What would settle it (cheap): the desk search already filed as research row acute-chronic-wound-cleansing-irrigation.3.us-clinician-hocl-belief-and-cleanser-purchase-influence, then twenty structured calls with US wound clinicians on the clinician-belief study designed under REQ-0226 Design the primary research that would… (fieldwork the owner must authorise); the Urgo randomized trial of Vashe against saline (NCT07440797 (a ClinicalTrials.gov registration number)) reads out later and is not something anyone here can speed up
claim 116unconfirmed, claim 141unconfirmed, claim 44unconfirmed, claim 42unconfirmed, claim 10unconfirmed, claim 173unconfirmed, claim 1unconfirmed, claim 93verified, claim 87verified, claim 107verified, claim 142verified, claim 101verified, claim 94verified, claim 48verified, claim 175verified
Each row is one thing this idea has to be true. Ordered by what a failure would cost and, inside that, by what it costs to find out — for this idea only; bands never compare between ideas.
Seven chairs, each answering from its own field. The verdict, and the first condition it set.
| Regulatory | conditional | C1 Proposed 21 CFR (Title 21 of the Code of Federal Regulations) 878.4019(a)(1) limits antimicrobial preservatives in liquid wound washes to nonsterile or multiple-use single-patient products. The P1 per-patient HOCl bag bag is therefore inside the proposed… +11 more condition(s) the position → |
| Clinical & Scientific | conditional | C3 A randomized controlled trial of at least 100 adults with chronic VLU, DFU (diabetic foot ulcer) or pressure injuries has published a statistically significant improvement in the proportion completely healed at 12 weeks… +5 more condition(s) the position → |
| Market Access | conditional | C4 It would have to be true that 42 CFR 414.22(b)(5) bases practice expense RVUs "entirely on relative practice expense resources". It would also have to be true that 414.22(b)(5)(i) applies facility PE… +4 more condition(s) the position → |
| Technology & R&D | conditional | C1 A hand-compressed flexible IV bag through a 19-gauge outlet reaches a median peak of only about 4 psi (range 2-5.5 psi). The same bag in a 400 mmHg (millimetres of mercury) cuff reaches 6-10 psi. This is why P1 per-patient HOCl bag's head… +7 more condition(s) the position → |
| Operations & NPI | conditional | C1 Irrisept K240552 (an FDA 510(k) clearance number) is manufactured as two separately sterilized sub-assemblies joined at the point of use, an aseptically filled Blow-Fill-Seal bottle and EO-sterilized pouched accessories. That is now… +11 more condition(s) the position → |
| Legal & IP | abstains | C1 Independent claim 1unconfirmed of US 8,871,278 B2 The single-use head is keyed to this… is limited to an electrolysed-NaCl HOCl solution or hydrogel with added bicarbonate/carbonate DIC (300-1500 mg/L, DIC:AFC no more than 5:1), 100-500 ppm AFC, pH… +19 more condition(s) the position → |
| Commercial | conditional | C1 The referrer, or a party it can bring in, holds or can license the right to make the Aquaceso hardware and to sell it with an HOCl solution. Under P1 per-patient HOCl bag this matters in a narrower way. P1 per-patient HOCl bag's head needs a… +7 more condition(s) the position → |
A position is not evidence: it cites the file's tags and issues none. blocks opens an impact review and kills nothing.
Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.
2 claim(s) the Verifier found to be false — a refuted claim is a finding, and the loop owes each one an answer.
Two, answering different questions: a written answer from the referrer on who makes and owns the Aquaceso design (score-mover), and twenty structured calls with US value-analysis committees and supply buyers on Commercial's instrument B1 US hospitals (decision-mover).
Only verified counts toward a score. A low count is usually a statement about the tooling (an absent data file, an unset key) rather than about the idea.
Re-run 2026-10-04 on the second Stage 4 Verified Composite (44/100 unscaled, 95% of weight covered, 8/9 factors), after the research pass and the Verifier's pass over claims 65-118. Verified claims only; no Stage 2 draft score is read. This supersedes the earlier 2026-10-04 run on 42/100; none of the four core factor scores moved.
hcpcs) and a verified non-coverage finding (claim 29verified,
policy article A54563 lists A6260 wound cleansers and irrigating solutions as non-covered
under the Part B surgical dressing benefit). The facility bundles are now each verified from
regulation text — OPPS (claim 65verified), SNF consolidated billing (66) and the home health
episode (67). No payment or coverage claim supports a pathway. The 1/5 reads "every
separately payable channel checked is closed", not "a code exists".
refuted on inventor attribution only; claim 79verified restates it and
verifies.
stage: stays verified. Cleared means only that no verified evidence says
kill. It is not an approval.
wrapped is not an approval — it means a human can now read this.
No human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one. The packet is wrapped, so it can be read now.
Runs only after a human shortlists the idea.
Converged — which is not an approval either way. A blocks verdict opens an impact review; it kills nothing.
evidence-gated — read off this idea's own decision queue. A state, not a rank, and never comparable between ideas.
Click any step to see what it holds for this idea. donecurrentloopinghuman only
## Wrap section, as writtenThe packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. ⚑ The shape changed during this run (pivot P0 the original shape → P1 per-patient HOCl bag, recorded as a redesign on 2026-10-04): what is described here is not the kit as first referred. A system for cleaning acute and chronic wounds at each dressing change, in US hospitals, outpatient wound clinics, nursing homes and home care. It has two parts. A sterile bag of saline preserved with hypochlorous acid is opened once and kept for one patient over a labelled number of days. A fresh, single-use spray head with three nozzles and a splash shield is plugged into that bag at every session, and the nurse squeezes a chamber in the head to push the fluid out at the pressure wound guidelines recommend (4-15 psi). It started as the referrer's "Aquaceso" irrigator (bag, three-nozzle head, splash shield, warmed tap water or irrigation fluid), with hypochlorous acid in place of water. It changed shape because FDA's 2023 proposed rule for wound washes accepts hypochlorous acid as a preservative only in a wash that is nonsterile or reused for one patient, not in a sterile single-use product, and because a bag squeezed by hand reaches only about 4 psi. Warming was dropped. On the label the hypochlorous acid only keeps the opened bag from growing organisms; it makes no claim to kill germs in the wound or help healing, since that would make it a drug, and no adequately sized trial showing it beats saline has been found. No US payer pays for it separately (Medicare lists wound cleansers as non-covered, and facility payments are bundled), so a facility would buy it out of its own supply budget. It is coded to existing FDA wound-wash and irrigation routes, and in Europe it would be a medical device under the MDR, which has not been checked here.
What would have to be true, quoted from each deck's load-bearing condition:
The assessment's decision queue says which of these the business dies without. Its top two:
fatal.
Cheapest next test: Two, answering different questions: a written answer from the referrer on who makes and owns the Aquaceso design (score-mover), and twenty structured calls with US value-analysis committees and supply buyers on Commercial's instrument B1 US hospitals (decision-mover).
Where the evidence actually stands. wrap_status.py: 9/9 factors scored, 4/4 core, 94 of 212 claims verified (98 unconfirmed, 18 unverified, 2 refuted). The Verified Composite is 44/100 over 8/9 factors and was computed over claims 1-118, before the pivot; the Gate Check cleared it (no kill condition fired), which is not an approval. The two refuted claims (55 and
181). Claims 195-212 were appended by the assessment, business case and decks after the last Verifier pass and have not been checked. Assessment posture: evidence-gated.
Blocked on tooling, not on a finding — none of these is evidence that something does not exist:
unconfirmed by jurisdiction rule. No connector reads EU
MDR notified-body records, EUDAMED, TED/EU-Supply tender documents or Danish sources, and
the TED host blocks automated fetch. The referrer's home market is unchecked, not negative.
patent-status/patent-scan are missing from claimlib.py's replay list, so
those lookups do not re-check automatically. No freedom-to-operate landscape has been run;
"nothing found" from a sweep is not a clear field.
apc, drg unconfigured), and the
cached DME (durable medical equipment) policy-article rows have a blank codes column, so coverage A6260 reads
"refuted" mechanically; Medicare non-coverage rests on the article text read via the CMS
coverage API (claim 29verified).
unverifiable by design; no dollar market size
exists (market model: not computable, 1 of 10 legs verified).
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 4 | Claims 4, 6, 7, 8, 9, 14 (four HOCl FRO solution predicates with HOCl as a preservative, plus a solution-and-applicator kit cleared as one FRO device), scored against the stated mechanical-cleansing intended use. Held below 5 by claims…the rest of this reasoning11-12: if proposed rule 2023-26209 has been finalized, the route becomes a Class II (FDA device class II) 510(k) with special controls, or Class III (FDA device class III). Also held down by claim 19unconfirmed, since FDA's reading of the hardware is unresolved. claim 20unconfirmed shows that an infection claim would turn the kit into a drug, which the label avoids. | The FDA 510(k) summaries for K123072, K232080, K142592, K243415 and K240552, plus a Federal Register search for a final rule under Docket FDA-2023-N-3392. All free, under an hour. |
| Reimbursement pathway | 1 | Claims 28, 29, 30, 31, 32, 33. Code A6260 exists (28) but is believed non-covered under the surgical dressing benefit (29). Facility settings pay supplies inside a bundle (30), and irrigation is not separately billable (31-32). So there is…the rest of this reasoninga code but no pathway: the kit sells from supply budgets on cost-in-use (33). Below the 2/5 floor. | The text of LCD (local coverage determination) L33831 (a Medicare local coverage determination number) and article A54563 in the CMS Medicare Coverage Database, plus 42 CFR 419.2(b) on eCFR. Free, under an hour. |
| TAM | 3 | Claims 34, 35 give the denominator of 8.2-10.5M Medicare beneficiaries with wounds. That counts people, not irrigations, and is Medicare-only. All three multipliers are open: irrigations per wound (36), kit price (37) and the share of…the rest of this reasoningencounters that use pressurized irrigation (38). The 3 is a triage guess on a large, partly evidenced base. | PubMed records for PMID (PubMed identifier) 37415496 and 29304937 settle the denominator for free. Price and addressable share need a licensed wound-care market report or GPO contract prices for Vashe/Puracyn Plus, which a human must attach. |
| FTO / IP | 2 | Claims 52, 56, 58. On the solution side, the stabilized-HOCl family under US 8,871,278 is believed live to about 2032 and held by Urgo (52). On the device side, the Schultz splash-shield family may run into the 2030s (56). The multi-nozzle…the rest of this reasoninghead, warmed bag and co-pack field is unexamined (58). Older shield patents are believed expired (54, 55, 57), and foundational HOCl patents too (53). Not "blocked" on anything known. Scored low because live families sit on both halves and nothing has been read. | Legal status and independent claims of US 8,871,278 and its family, and of US 8,002,757, 8,672,904 and 10,576,198, from USPTO Patent Center. Free to pull; reading the claims against the kit is a counsel task costing a few thousand dollars. |
| Moat / defensibility | 1 | Claims 3, 6, 59, 54, 55, 57. HOCl in irrigation bags is already sold (6), so the irrigant is not protectable (59). Shield prior art goes back decades (54, 55, 57). Defensibility would rest on head/shield design IP and a cleared kit (59),…the rest of this reasoningand whether anyone can license the Aquaceso hardware is an unchecked assumption (3). | A written answer from the referrer on who owns the Aquaceso design, plus an Espacenet/DKPTO search for patents held by its maker. A human ask of days. |
| Mechanism & clinical risk | 3 | Claims 40, 41, 7. Irrigation at 4-15 psi is a long-established mechanism (40-41), and the HOCl predicates cleared on bench data alone (7). Lowered by two design risks no one has tested: whether HOCl stays stable when warmed in the bag…the rest of this reasoning(50), and clinician aerosol/chlorine exposure (51). Also, no prototype exists (63). The HOCl efficacy literature is weak (39, 44, 45, 46), but the label does not depend on it. | A contract-lab bench test of free available chlorine after warming to about 37 C and after flow through the three nozzles, with a pressure reading at the nozzle. A few weeks and low thousands of dollars. |
| Capital intensity & time-to-revenue | 3 | Claims 7, 12, 17, 63, 3. The 510(k) evidence is bench-only (7), and the hardware alone would be Class I exempt (17). Costs come from filling sterile HOCl into bags with a 12-month stability programme (7, 63), from the timing risk if the…the rest of this reasoningproposed rule is finalized (12), and from the unresolved hardware rights (3). | A CDMO quote for sterile HOCl fill into flexible bags with 12-month stability, or supply terms from an incumbent HOCl maker. A human request taking weeks. |
| Competitive intensity | 2 | Claims 60, 6, 14, 4, 7, 8. At least four HOCl FRO cleansers are on the market. Puracyn Plus already sells HOCl in 1-3 L irrigation bags (6), and IRRISEPT is a cleared single-use, self-contained irrigation kit (14). Add Prontosan, pulsatile…the rest of this reasoninglavage and the Zerowet shields (60). Not a 1, because nobody is known to sell the integrated head, shield and HOCl bag. | Searches of FDA 510(k) clearances under product codes FRO and FQH since 2020, plus the FDA recall database for both codes. Free, minutes. |
| Strategic fit & portfolio balance | 2 | claim 64unconfirmed. No seed and no domain dossier, so it opens a new domain rather than building on one. It is low-capital, but with no separate payment (33) it is a weak cash-generative spoke in the US. The referral and the DK/EU angle (25-27) are…the rest of this reasoningrelationship value the rubric does not score. | A Tier 3 portfolio review against knowledge-base/_index/status.md. Internal; no external source settles it. |
All eight wrap criteria are met.
Source file: knowledge-base/candidates/idea-023.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.
_shared/plain-language.md